Emend for Multiple-day Emetogenic Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

November 30, 2008

Study Completion Date

January 31, 2009

Conditions
NauseaVomiting
Interventions
DRUG

aprepitant, ondansetron, dexamethasone

"On day 1, the subject will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 125mg. On days 2 to THE LAST DAY OF THE MODERATELY-HIGH TO HIGHLY EMETOGENIC CHEMOTHERAPY, subjects will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 80mg. All anti-emetics should be give one hour before starting chemotherapy administration.~FOR TWO DAYS AFTER RECEIVING CHEMOTHERAPY, the subject will be prescribed oral dexamethasone 4mg every 12 hours and oral aprepitant 80 mg every day.~FOR RESCUE, the subject will be prescribed prochlorperazine 10 mg oral every 4 hours as needed for nausea and prochlorperazine 10 mg intravenous every 4 hours as needed for vomiting."

Trial Locations (1)

60612

University of Illinois Medical Center, Chicago

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Northwestern Memorial Hospital

OTHER

lead

University of Illinois at Chicago

OTHER

NCT00711555 - Emend for Multiple-day Emetogenic Chemotherapy | Biotech Hunter | Biotech Hunter